Back to top

Image: Bigstock

Top Ranked Income Stocks to Buy for December 30th

Read MoreHide Full Article

Here are four stocks with buy rank and strong income characteristics for investors to consider today, December 30th:

Invesco Ltd. (IVZ - Free Report) : This investment manager has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.2% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 7%, compared with the industry average of 2.3%. Its five-year average dividend yield is 4.1%.

Invesco Ltd. Dividend Yield (TTM)

Invesco Ltd. Dividend Yield (TTM)

Invesco Ltd. dividend-yield-ttm | Invesco Ltd. Quote

MFA Financial, Inc. (MFA - Free Report) : This real estate investment trust has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.

This Zacks Rank #2 company has a dividend yield of 10.4%, compared with the industry average of 8.4%. Its five-year average dividend yield is 10.6%.

MFA Financial, Inc. Dividend Yield (TTM)

MFA Financial, Inc. Dividend Yield (TTM)

MFA Financial, Inc. dividend-yield-ttm | MFA Financial, Inc. Quote

Newtek Business Services Corp. (NEWT - Free Report) : This business development company that offers financial and business services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.9% over the last 60 days.

This Zacks Rank #2 company has a dividend yield of 12.5%, compared with the industry average of 8.4%. Its five-year average dividend yield is 8.5%.

Oxford Square Capital Corp. (OXSQ - Free Report) : This business development company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.5% over the last 60 days.

This Zacks Rank #2 company has a dividend yield of 14.9%, compared with the industry average of 8.4%. Its five-year average dividend yield is 15.1%.

See the full list of top ranked stocks here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>